PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

Gain expert perspectives on the current and future use of PARP inhibitors in metastatic breast cancer with this triple-certified online program, which features an on-demand Webcast capturing a dynamic CCO symposium at SABCS 2018, downloadable slides from the symposium, and expert-authored commentaries. 

ClinicalThought

Have you started testing your patients with MBC for germline BRCA mutations? BRCA testing is important to guide treatment with PARP inhibitors.

Lee Schwartzberg, MD, FACP Released: September 21, 2018
Jointly provided by National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC
NCCN Logo

Ann Gianola, MA
Manager, Continuing Education Accreditation
National Comprehensive Cancer Network
275 Commerce Drive, Suite 300
Fort Washington, PA 19034

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by educational grants from
AstraZeneca
Pfizer Inc.
Tesaro

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?